Lofexidine in Combination with Oral Naltrexone for Opioid Use Disorder Relapse Prevention: A pilot Randomized, Double-Blind, Placebo-Controlled Study.

CONCLUSION AND SCIENTIFIC SIGNIFICANCE: Although preliminary, these findings suggest that LFX at doses up to 2.4 mg/daily was safe and improved control over opioid cravings. Among those who tolerated the medication, LFX/NTX significantly improved the opioid craving, delayed return to opioid use, and improved treatment compliance and completion rates. These findings support further assessment of LFX dose titration schedule along with the adjunctive use of LFX with NTX treatment to enhance opioid relapse prevention. (Am J Addict 2019;00:1-9). PMID: 31448846 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31448846?dopt=Abstract

Source: American Journal on Addictions - August 25, 2019 Category: Addiction Authors: Hermes G, Hyman SM, Fogelman N, Kosten TR, Sinha R Tags: Am J Addict Source Type: research

More News: Addiction | Hepatitis | Men | Statistics | Study